NCI-2024-02382

A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

This is a platform study testing different combinations of RAS(ON) inhibitors in patients with RAS-mutated Non-Small Cell Lung Cancer (NSCLC). RAS mutations are changes in a gene that can cause cancer cells to grow uncontrollably. The study is designed to find the most effective combination of treatments that target these mutations in order to help stop the cancer from growing.

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

RAS mutations: Ras mutations are alterations in the RAS genes (KRAS, NRAS, HRAS) that encode proteins involved in cell signaling pathways. These mutations are commonly found in various types of cancer and play a crucial role in oncogenesis (cancer development).

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06162221

Clinical Trial Site: Columbia

To see all available clinical trials click here.